C3L-02601
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71.54825462
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFEC-TTM6-A-1-1-R-A742-41 | — | C | 0.922 |
| 2 | SRR10900576 | — | — | 0.921 |
| 3 | s0122206 | — | — | 0.918 |
| 4 | TCGA-CV-7433-01A-11R-2132-07 | — | — | 0.913 |
| 5 | EPT0509 | EPN | EPN Tumor | 0.912 |
| 6 | 24d909f2-cdc8-4509-91d5-e18fffcf90eb | — | — | 0.904 |
| 7 | MDT-AP-2029 | Med | Medulloblastoma | 0.898 |
| 8 | 007344ca-2cc3-4837-9b44-824040f7ac16 | — | — | 0.898 |
| 9 | 02faba9d-8eda-4967-995d-61a0c13b843c | — | — | 0.897 |
| 10 | BS_0QYS36NR | EPN | EPN Tumor | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| APOPTOSIS | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |